Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
Hims & Hers Health (HIMS) Chief Financial Officer Oluyemi Okupe executed a planned sale of 23,107 shares of Class A Common Stock on June 23, 2025, at an average weighted price of $47.2483 per share (range: $47.15 - $47.43).
Following the transaction, Okupe's holdings include:
- 63,222 shares held directly
- 70,575 shares held indirectly through the Oluyemi Okupe Separate Property Trust
The sale was conducted under a Rule 10b5-1 trading plan established on May 31, 2024, demonstrating pre-planned, compliant insider trading activity. This transaction represents a partial reduction of the CFO's direct holdings while maintaining significant equity stake in the company through both direct and trust ownership.
A Form 144 filing from Hims & Hers Health reveals a proposed sale of 69,431 shares of common stock with an aggregate market value of $2,914,713.38. The sale is planned to be executed through Goldman Sachs on the NYSE, with an approximate sale date of June 23, 2025.
The securities being sold were acquired through multiple compensation events:
- 37,186 shares from stock options (February 2022)
- 9,138 RSUs (June 2024)
- 23,107 RSUs (June 2025, across three grants)
The filing also discloses previous sales by Oluyemi Okupe over the past 3 months, totaling approximately 45,923 shares between April-May 2025, with total gross proceeds of about $1.98 million. These transactions demonstrate a consistent pattern of insider sales, with most individual transactions ranging from ~1,000 to ~9,200 shares.